William G. Wierda, MD, PhD, on Using Venetoclax in CLL

Posted: Monday, August 5, 2019

What steps do you take to prevent tumor-lysis syndrome associated with targeted agents in CLL such as idelalisib, ibrutinib, and venetoclax?